Kornimate/medical-research-clean huggingface dataset:
variation of spatiotemporal parameters in school children carrying different backpack loads

Conditions: Child, Only; Gait, Unsteady

Summary: backpacks (bp) represent the method most used by students to transport external cargo. previous studies cite that between 4.7% and 38% of children carry daily bp loads greater than 20% of their body mass. the purpose of this study was to analyze spatiotemporal parameters of gait in children using varyingly loaded bps.

this study examined 231 schoolchildren (118 boys, 113 girls) aged six to 12 years, carrying a traditional bp to manipulate loading (crossing backpack children arpenaz 7 litres, junior red quechua). the inclusion criteria were: age between six and 12 years, no pain in the lower limb and back at the time of examination. the exclusion criteria were: recent injury to the lower limb and back, alterations in the foot bones, congenital structural changes to the ankle, flatfoot associated with cerebral palsy, surgical treatment of foot or lower leg, or any genetic, neurologic or muscular conditions. the parents were provided with information about the study, and those consenting for their children to participate, also completed a questionnaire. the children were fully informed of the procedures involved and gave assent. all procedures were in accordance with the ethical standards of the institution of university of malaga (ceuma 91/2016h) and with the 1964 helsinki declaration. load was added to the bps in increments of 5%, 10%, 15% and 20% of the child's body weight. spatio-temporal parameters were measured with the optogait® system. two examiners were responsible for the system software and collecting data. general information, including height and weight, were recorded. to measure gait parameters, the protocol used for the optogait reliability testing was used. this involved the children walking on a walkway at a comfortable speed, repeating this walk three times and calculating the mean speed. prior to data collection, the children performed one familiarization trial for five minutes. children were asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the bp placed correctly. as the children started walking, the researchers selected the foot of the first step inside the bars, in the optogait software. after being instructed to 'walk slowly at a comfortable speed', the children walked from a point two metres in front of the bar and stopped at a point two metres behind the last bar, to minimize effects of acceleration and deceleration

Eligibility criteria:
inclusion criteria: * the inclusion criteria were: age between six and 12 years, no pain in the lower limb and back at the time of examination. exclusion criteria: * the exclusion criteria were: recent injury to the lower limb and back, alterations in the foot bones, congenital structural changes to the ankle, flatfoot associated with cerebral palsy, surgical treatment of foot or lower leg, or any genetic, neurologic or muscular conditions.
perceptions of rehatt mixed reality system

Conditions: Stroke

Summary: the study aims to explore the patients' perspective on usability and feasibility of the rehatt™ mixed-reality system during upper limb, gait and balance function rehabilitation.

mixed reality is an immersive technology that can integrate virtual objects into the real world and adaptive scenarios. it offers the opportunity to train physical and cognitive aspects in stroke patients. the patients' perspectives were assessed with a semi-structured interview.

Eligibility criteria:
inclusion criteria: * first ischaemic or hemorrhagic stroke, * one-sided hemiparesis, * adequate cognitive abilities. exclusion criteria: * severe cognitive impairment, * aphasia, * known presence of an epileptic seizure in the last year, * other orthopaedic and neurological diseases affecting sensory or motor functions, * inability to sit independently, * severe visual impairment, * severe depression.

Keywords: rehabilitation mixed reality motor rehabilitation patients' perspective
project impact immunizations (improving america's communities together)

Conditions: Influenza

Summary: the primary objective of this study is to evaluate how implementing an innovative care model that provides the pharmacist access to a patient's vaccine history at the point-of-care impacts the pharmacist's ability to identify unmet vaccination needs and increase vaccination rates for routinely recommended adult vaccinations.

this is a multi-site, observational study investigating the impact of implementing an innovative care model on the pharmacist's ability to identify unmet vaccination needs and increase vaccination rates for routinely recommended adult vaccinations. the innovative care model enables the pharmacist to utilize a bi-directional iis to assess patients' vaccination histories, identify unmet vaccination needs, and document the care provided. data will be collected in the bi-directional iis. aggregate de-identified data will be reported to the researchers at the midpoint and conclusion of the study. the project duration has been established to allow sufficient time for each pharmacy to implement the innovative care model and monitor each pharmacy for a 6-month study period. the american pharmacists association (apha) foundation has an a priori intent to publish the project results.

Eligibility criteria:
inclusion criteria: * individuals eligible to be enrolled in the study include any person at least 18 years of age receiving an influenza vaccination from a participating pharmacy site. exclusion criteria: * n/a

Keywords: influenza vaccine public health preventable disease vaccine history point-of-care
efficacy and safety study for ecabet ophthalmic solution for treating dry eye syndrome

Conditions: Dry Eye Syndromes

Summary: the purpose of this study is to determine whether ecabet ophthalmic solution is an effective treatment for dry eye syndrome


Eligibility criteria:
inclusion criteria: * agree to avoid systemic \& topical ophthalmic meds \& disallowed meds * have a best corrected visual acuity (bcva) of 20/40 with pinhole or better in each eye * diagnosis of moderate dry eye syndrome exclusion criteria: * uncontrolled ocular or systemic disease that could interfere with study * diagnosis of sjogren's syndrome, lacrimal obstruction, reflex, lid-related or contact lens-related dry eye syndrome(des); significant anterior blepharitis or meibomianitis * contraindications or hypersensitivity to use of study meds or components * wear contact lenses * secondary dry eye to surgery * eye surgery (including laser) within 6 months * use of systemic or topical ophthalmic meds within 14 days * punctal plugs in one or both eyes in place for \<45 days * permanent occlusion of the lacrimal puncta
urine omics predicting io therapy responses in muc patients

Conditions: Metastatic Urothelial Carcinoma

Summary: the study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving io-based therapies for metastatic urothelial carcinoma.

this is a multi-center single-arm translational study where patients with muc who are about to receive pre-determined io-based anti-tumor therapy will be invited to participate the study. after signing the approved informed consent, eligible and consenting subjects will donate their fresh urine samples for subsequent untargeted metabolomics and proteomics study via gs-ms/ms and/or lc-ms/ms to identify potential metabolite and protein markers that are able to predict efficacy and side effects of io-based therapies. all subjects in the first-line, maintenance after 1st line, second-line, or subsequent lines of io-based therapy will be invited and recruited, but those who have received any io-based therapy before the study can not be recruited.

Eligibility criteria:
inclusion criteria: * 1. age \> 20 years * 2. subjects diagnosed as metastatic urothelial carcinoma (muc) * 3. subjects who are about to receive io-based therapy * 4. ecog performance 0, 1, 2, and 3 * 5. life expectancy 3 months * 6. egfr \> 15 ml/min/1.73 m2 (stage iv chronic kidney disease or better) * 7. willing to sign the informed consent form exclusion criteria: * 1. subjects not willing to sign the informed consent form * 2. subjects with active infection or active urinary tract infection, as shown by urinary wbc \> 5/hpf * 3. subjects having co-existing other malignancies that need active treatment. those with other malignancies that do not need active treatment are allowed to join the study. * 4. subjects taking any immune-modulating agents, including but not limited to corticosteroid, immune-suppressants, etc. at the discretion of recruiting investigators * 5. subjects who have taken any cpis before. however, subjects who have received intravesical or intrapelvic bcg instillation are allowed to enroll. * 6. subjects who have received anti-fgfr therapy, enfortumab vedotin or other systemic therapies within 12 weeks of screening are not allowed. however, subjects who had a washout period of the above agents for \>12 weeks are allowed to enroll. subjects who have received or are receiving cytotoxic chemotherapy are allowed to join the study.

Keywords: urothelial carcinoma biomarkers clinical responses io-based therapies metabolomics proteomics urine
zinc resistant starch project

Conditions: Enteropathy

Summary: broad - to examine the result of feeding rs to 3-5 year old rural malawian children on zinc homeostasis and environmental enteropathy (ee). specific - 1. to measure zinc status using a dual zinc stable isotope assay before and after administering resistant starch (rs) in 20 children. 2. to measure intestinal function using a site-specific sugar absorption test before and after administering rs in 20 children. 3. to determine the relationship between rs and zinc homeostasis. 4. to determine the relationship between rs and environmental enteropathy.

a total of 20 (10 m, 10 f) stunted rural malawian children aged 36-60 months will be studied to determine if there is an effect of feeding rs on zinc homeostasis and environmental enteropathy. these children are at high risk for zinc deficiency and environmental enteropathy by their demographic characteristics. children will first have a quantitative assessment of zinc homeostasis where each child is given 2 zinc stable isotopes, one by mouth and another intravenously, which is followed by a stool and urine collection of 4 days. zinc isotopes are quantified in the feces and urine, and these values are used to calculate the primary outcome, net zinc balance. this is followed by an assessment of environmental enteropathy quantitatively measured using the non-invasive site specific sugar absorption test, where each child drinks 100 ml of a sugar solution and a urine collection follows. the quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. then the children will receive a dietary supplement, corn starch that has been modified to reduce its dietary absorption, for 5 weeks, which they will add to their phala. the rs is a standard food product that has been used safely in many millions of people for several decades. after taking this rs for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated on the children to see if they have improved. these results will offer preliminary data as to whether rs might be used effectively on a large scale in the community to alleviate zinc deficiency and/or environmental enteropathy.

Eligibility criteria:
inclusion criteria: * any stunted, otherwise healthy child aged 36-60 months living close to the chipalonga health center. stunting will be defined as height-for-age z-score (haz) \< -2. children will be selected on the basis of having the lowest weight-for-height z-scores (whz), and by dietary surveys on which their caretakers report consuming animal source foods \< twice per month. previous field work indicates about 80% of children are stunted and almost all children consume animal source foods \< twice per month. exclusion criteria: * children who are not permanent residents in the village. additionally, children with severe chronic illness such as cerebral palsy, and those who are receiving other supplementary food, or those who are participating in another research study are all ineligible to participate.
nebulised 3% hypertonic saline versus 0.9% saline for treating patients hospitalized with acute bronchiolitis

Conditions: Bronchiolitis

Summary: bronchiolitis is an acute viral infection of the lower respiratory tract. it is most commonly caused by respiratory syncytial virus (rsv). only supportive therapy, including suctioning nasal secretions, water-electrolyte balance maintenance, and oxygen supplementation when needed, is recommended. the inhalation of 3% hypertonic saline is not recommended in bronchiolitis management. however, a recently published meta-analysis revealed that the inhalation of hypertonic saline can reduce the risk of hospitalisation for outpatients with bronchiolitis, while resulting in a shorter length of hospital stay and reduced severity of respiratory distress for inpatients, although the evidence is of low certainty. the aim of the study is to assess the efficacy of nebulised hypertonic saline for the treatment of children hospitalised with bronchiolitis.


Eligibility criteria:
inclusion criteria: 1. children admitted to the hospital with the clinical diagnosis of acute bronchiolitis, which is defined as an apparent viral respiratory tract infection associated with airway obstruction manifested by at least one of following symptoms: * tachypnoea (who definition). * increased respiratory effort manifested as follows: 1. nasal flaring; 2. grunting; 3. use of accessory muscles; 4. intercostal and/or subcostal chest wall retractions; 5. apnoe. * crackles and/or wheezing. 2. aged 5 weeks - 24 months old. 3. a caregiver must provide written informed consent. exclusion criteria: 1. infants hospitalised with severe bronchiolitis (requiring mechanical ventilation or intensive care, or oxygen saturation \< 85% on room air). 2. history of prematurity (gestational age \<34 weeks). 3. diagnosis of a clinically significant chronic disease (cardiac, respiratory, neuromuscular, or metabolic). 4. immunodeficiency. 5. gastro-oesophageal reflux. 6. diagnosis or suspicion of asthma. 7. inhaling a nebulised 3% hypertonic saline solution within 12 hours before enrolment. 8. inhaling bronchodilators within 24 hours before enrolment. 9. inhaling steroids within 24 hours before enrolment. 10. systemic steroid therapy in the preceding 2 weeks.

Keywords: hypertonic saline infants rct
study of near-infrared imaging with indocyanine green for detection of sentinel lymph nodes in people with vulvar cancer

Conditions: Vulvar Cancer

Summary: the purpose of this study is to compare two types of imaging for sentinel lymph node (sln) mapping in people with early-stage vulvar cancer. the researchers will compare indocyanine green near-infrared (icg-nir) imaging with lymphoscintigraphy. all participants in this study will be scheduled for standard surgical treatment at memorial sloan kettering cancer center (msk). this surgical treatment includes sln mapping (with both lymphoscintigraphy and icg-nir imaging) and sln biopsy.


Eligibility criteria:
inclusion criteria: * ≥18 years of age * newly diagnosed with vulvar cancer and scheduled to undergo sln biopsy (patients with squamous cell carcinomas and melanomas will be included) * primary tumor ≤4 cm in size * for patients with squamous cell carcinoma, \>1 mm of invasion is required exclusion criteria: * clinically or radiographically enlarged inguinofemoral lymph nodes (if imaging is performed) * presence of distant metastases * absolute contraindication to radiocolloid tc-99 or icg * nonsquamous or nonmelanoma histologic subtype

Keywords: near-infrared imaging indocyanine green sentinel lymph nodes 23-310
study of actr707 in combination with rituximab in subjects with relapsed or refractory b cell lymphoma

Conditions: Lymphoma

Summary: this is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous t cell product (actr707) in combination with rituximab in subjects with refractory or relapsed cd20+ b cell lymphoma.


Eligibility criteria:
inclusion criteria: * signed written informed consent obtained prior to study procedures * histologically-confirmed relapsed or refractory cd20+ b-cell lymphoma of one of the following types, with documented disease progression or recurrence following the immediate prior therapy: dlbcl (regardless of cell of origin or underlying molecular genetics), mcl, pmbcl, gr3b-fl, th-fl (prior dx of fl before transforming to dlbcl). * biopsy-confirmed cd20+ expression of the underlying malignancy with disease progression following immediate prior therapy * at least 1 measurable lesion on imaging. * must have received adequate prior therapy for the underlying cd20+ b-cell lymphoma, defined as an anti-cd20 mab in combination with an anthracycline-containing chemotherapy regimen (i.e. chemo-immunotherapy) and at least one of the following: * biopsy-proven refractory disease after frontline chemo-immunotherapy * relapse within 1 year from frontline chemo-immunotherapy and ineligible for autologous hematopoietic stem cell transplant (auto-hsct) * for subjects with dlbcl, pmbcl, and gr3b-fl: relapsed or refractory disease following at least 2 prior regimens or following an auto-hsct * for subjects with th-fl: relapsed or refractory disease following at least 2 prior regimens or following an auto-hsct. at least 1 prior regimen with an anti-cd20 mab in combination with chemotherapy is required following documented transformation * for subjects with mcl (confirmed with cyclin d1 expression or evidence of t(11;14) by cytogenetics, fluorescent in situ hybridization (fish) or polymerase chain reaction (pcr): relapsed or refractory disease after at least 1 prior regimen with chemo-immunotherapy (prior auto-hsct is allowable) * ecog 0 or 1 * life expectancy of at least 6 months * platelet count greater than 50,000/µl exclusion criteria: * known active central nervous system (cns) involvement by malignancy. * prior treatment as follows: * alemtuzumab within 6 months of enrollment * fludarabine, cladribine, or clofarabine within 3 months of enrollment * external beam radiation within 2 weeks of enrollment * mab (including rituximab) within 2 weeks of enrollment * other lymphotoxic chemotherapy (including steroids except as below) within 2 weeks of enrollment * experimental agents within 3 half-lives prior to enrollment, unless progression is documented on therapy * clinically significant cardiac disease * clinically significant active infection * clinically significant cns disorder * clinical history, prior diagnosis, or overt evidence of autoimmune disease * known bone marrow involvement due to underlying malignant disease, in dose-escalation phase only

Keywords: cd20+ b cell actr actr707 relapsed refractory t cell t cell product adoptive t cells gene therapy
tenofovir alafenamide(taf) reduces the risk of hepatocellular carcinoma(hcc) recurrence

Conditions: HCC Patients After Curative Treatment With Low HBV Viral Load

Summary: hepatocellular carcinoma(hcc) is prevalent in the hepatitis b virus(hbv) infection endemic areas. for early stage of hcc, surgical resection, radiofrequency ablation (rfa) or microwave ablation (mwa) are the main treatment options. however, the risk of recurrence is as high as 50% in 5 years by surgical resection or 60-70% in 5 years by rfa. in average, the recurrence rate of hcc at 2 years is 30%. many factors are associated with the hcc recurrence, including hbv viral load, cirrhotic stage, tumor size, tumor number, vascular invasion, alpha-fetoprotein(afp) level and so on. of them, high hbv viral load is associated with the risk of hcc recurrence after surgical resection, especially on late recurrence. in one previous randomized controlled trial, patients who received lamivudine, adefovir dipivoxil, or entecavir had significantly decreased early recurrence of hcc, however, whether nucleos(t)ide analogues(nucs) can further reduce the risk of recurrence in patients with low viral loads (\<2000 iu/ml) is still unclear. in easl 2017 guideline, all patients with compensated or decompensated cirrhosis need antiviral treatment, with any detectable hbv dna level and regardless of alanine aminotransferase(alt) levels. in taiwan, even in chronic hepatitis b(chb) infection patients with hcc, nuc is not reimbursed if their hbv viral load was less than 2000 iu/ml. it is an important unmet medical need to understanding the role of taf in reducing the risk of recurrence in hbv-hcc patients with low hbv viral load (hbv dna\<2000 iu/ml) and significant liver fibrosis after curative treatment (the definition of significant liver fibrosis was based on reference. in our recent retrospective study, the risk of recurrence and survival are comparable between patients with and without nucs treatment before hcc development only if nucs treatment can be provided after curative treatment of hcc. however, a higher risk of recurrence was observed in cirrhotic patients with prior nucs treatment before hcc occurrence. it would be interesting to investigate the incidence of recurrence by switching to tenofovir alafenamide(taf) after curative treatment of hcc in patients already on nucs treatment.


Eligibility criteria:
inclusion criteria: * hbsag-positive for more than 6 months. * hcc after curative treatment (eight by surgical resection or rfa or mwa) with significant liver fibrosis (either by ishak≧2, metavir≧2, knodell≧3) or cirrhosis and hbv dna\<2,000 iu/ml. * the duration of curative treatment of hcc to study enrollment should be less than 90 days. * curative treatment is confirmed by contrast-enhanced ct or mr after the surgery/rfa/mwa. exclusion criteria: * child-pugh class b8-c. * active ev bleeding within 4 weeks. * history of hepatic encephalopathy or intractable ascites. * bclc c or d.